N-Methylmoranoline (MOR 14)

An inhibitor of glycoprotein processing and α-glucosidases

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥5837.00

4670.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajce45516
CAS: 69567-10-8
别名: 丙二腈,MOR 14; N-Methyl-1-deoxynojirimycin; N-Methylmoranolin
分子式: C7H15NO4
分子量: 177.2
纯度: >98%
溶解度: Soluble in DMSO
储存: Store at -20°C
库存: 现货

Background

N-Methyldeoxynojirimycin is an inhibitor of α-glucosidases and glycoprotein processing.¹ It inhibits the rabbit intestinal α-glucosidases sucrase and maltase (IC₅₀s = 0.068 and 0.46 ?g/ml, respectively) and R. niveus glucoamylase (IC₅₀s = 1.6 and 4.7 ?g/ml with starch or maltose as substrates, respectively).² It is selective for these enzymes over β-glucosidase (IC₅₀ = 363 ?g/ml). N-Methyldeoxynojirimycin inhibits highly pathogenic avian influenza (HPAI) oligosaccharide processing in HPAI-infected chicken embryo cells.¹ It reduces the cytopathic effect of HIV in infected Karpas-45 T cells.³ N-Methyldeoxynojirimycin also inhibits postprandial increases in blood glucose levels in sucrose-loaded rats (ED₅₀ = 5.8 mg/kg).

1.Romero, P.A., Datema, R., and Schwarz, R.T.N-Methyl-1-deoxynojirimycin, a novel inhibitor of glycoprotein processing, and its effect on fowl plague virus maturationVirology130(1)238-242(1983) 2.Yoshikuni, Y.Inhibition of intestinal α-glucosidase activity and postprandial hyperglycemia by moranoline and its N-alkyl derivativesAgric. Biol. Chem.52(1)121-128(1988) 3.Karpas, A., Fleet, G.W.J., Dwek, R.A., et al.Aminosugar derivatives as potential anti-human immunodeficiency virus agentsProc. Natl. Acad. Sci. USA85(23)9229-9233(1988)

Protocol

Kinase experiment:

The inhibitory action of N-Methylmoranoline against myocardial α-1,6-glucosidase is first examined in rabbit heart extracts. The substrate mixture contained 44 mM glycylglycine (pH 6.5), 12.5% rabbit liver glycogen, 2.5 mM [14C]glucose (20 μCi/μM), 2.1 mM EDTA, 4.1 mM mercaptoethanol, 0.02% gelatin, and N-Methylmoranoline (0, 0.01, 0.03, 0.1, 0.3, or 1.0 μM). This solution (16 μL) is warmed at 30°C for 2 minutes, and the reaction is then initiated by the addition of 4 μL of the rabbit heart homogenate. The reaction is stopped 60 minutes later by the addition of 20 μL of 0.2N HCl. An aliquot (30 μL) is spotted onto a Whatman GF/A glass fiber disk. The disk is immediately washed in 66% ethanol for 20 minutes three times each and dipped in 15 mL of acetone for 10 minutes. Then the disk is dried, and the [14C] activity incorporated into glycogen is measured with a liquid scintillation counter[1].

Animal experiment:

Rabbits: To investigate the infarct size-reducing effect of N-Methylmoranoline, 54 rabbits are assigned randomly into drug treatment or saline control groups. There are four drug treatment groups, ie, three preischemic treatment groups given 100 mg/kg, 50 mg/kg, or 25 mg/kg of N-Methylmoranoline 10 minutes before ischemia, and one prereperfusion treatment group given 100 mg/kg of the drug 5 minutes before reperfusion. In all treatments, the injected volume is <1 mL/kg body wt. After the treatment, the coronary artery is occluded for 30 minutes and reperfused. The blood pressure and heart rate are monitored throughout the experiment until 20 minutes after reperfusion and are recorded at baseline, at 0, 1, 3, 5, 10, 20, and 30 minutes of ischemia, and at 5, 10, and 20 minutes of reperfusion[1].

参考文献:

[1]. Arai M, et al. N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts. Circulation. 1998 Apr 7;97(13):1290-7.
[2]. Arai M, et al. Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor. Br J Pharmacol. 2001 Jul;133(5):635-42.
[3]. Nishida Y, et al. N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction. Heart Vessels. 2000;15(6):268-73.